“ANA’s are some of most commonly ordered tests but what exactly are they and what do you do with a positive ANA? Check out the Editor’s Pick for October to learn more,” says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.
Search results for: antinuclear antibody
Some Lupus Tests Yield False Results
The ACR’s Regional Advisory Council (RAC) has received several member reports of false results on antinuclear antibody (ANA) tests. The test screens for systemic lupus erythematosus, drug-induced lupus, and other diseases. Results are used to direct treatment, so accuracy is crucial.
Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Q&A with a Rheumatologist-Hospitalist
As rheumatology fellows around the country begin to explore various career opportunities, they typically look to academic rheumatology, private practice, industry and research. Vivek K. Murthy, MD, MSc, however, has carved a unique clinical pathway in both rheumatology and hospital medicine, merging his various skills and interests in medical education, diagnostic expertise and clinical problem…
A Case of Lupus Podocytopathy
Kidney involvement is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Collectively termed lupus nephritis, SLE with kidney involvement comes in many subtypes. The current classification by the International Society of Nephrology/Renal Pathology Society (ISN/RPS), however, does not include lupus podocytopathy, which, through various clinical and epidemiologic studies, has recently been…
What’s Holding Back Biomarker Innovation, & How Can We Solve It?
Think about it. Most rheumatology labs are stuck in the 1960s. Translational biomarker research looks excellent on paper and in theory. However, many barriers exist from the bench to the bedside. This article highlights this problem for the rheumatology community and proposes practical solutions. Case in Point For an example, let’s examine systemic lupus erythematosus…
A Case of Nodular Rash & Painful Joints
Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…
Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease
No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.
The Role of ANA Positivity in Patients with RA
Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses.
EULAR/ACR Criteria Identify SLE in Hospitalized Pericarditis Patients
NEW YORK (Reuters Health)—New European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria can be used to identify patients with systemic lupus erythematosus (SLE) in an unselected group of patients hospitalized for pericardial effusion, new findings show.1 “Overall, in patients with pericardial effusion and positive ANA, the diagnosis of SLE could be ruled out…
- 1
- 2
- 3
- …
- 10
- Next Page »